KAS
REGN icon

KPP Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

KPP Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-235
Closed -$247K – 269
2024
Q3 		$247K Hold
235
– – 0.06% 219
2024
Q2 		$247K Sell
235
-4
-2% -$3.88K 0.07% 207
2024
Q1 		$230K Sell
239
-4
-2% -$3.8K 0.06% 218
2023
Q4 		$213K Buy
+243
New +$200K 0.19% 117

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KPP Advisory Services's REGN Position: Q4 2024 in Review

KPP Advisory Services sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 235 shares — an estimated $247K sold.

KPP Advisory Services first reported a position in REGN in Q4 2023 and held it in 4 quarters. The position peaked at $247K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • KPP Advisory Services reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • KPP Advisory Services sold 235 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $247K.
  • KPP Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • KPP Advisory Services's Regeneron Pharmaceuticals position peaked at $247K in Q3 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on KPP Advisory Services's 13F filing for Q4 2024, filed 24 Jan 2025.